{
  "pmcid": "12091215",
  "sha256": "1c3c8d9922db9c1a0f051a547c73efbcb0b6790aa7ba77364126aad4f20ad441",
  "timestamp_utc": "2025-11-09T15:30:03.851553+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.7868253968254,
    "reading_ease": 46.26928571428573,
    "word_count": 252
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Methods.: This was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of NPC-21 for KT recipients with CMV donor-positive (D + )/recipient-negative (R − ) serostatus."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients were randomly assigned to receive monthly 6 or 12 mg/kg NPC-21, or placebo, in a 4:1:4 ratio."
      },
      "Participants": {
        "score": 1,
        "evidence": "KT recipients with CMV donor-positive (D + )/recipient-negative (R − ) serostatus."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were randomly assigned to receive monthly 6 or 12 mg/kg NPC-21, or placebo, in a 4:1:4 ratio."
      },
      "Objective": {
        "score": 1,
        "evidence": "In KT recipients, we assessed the efficacy and safety of fiztasovimab (NPC-21), an anti-CMV monoclonal antibody."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary efficacy endpoint was CMV infection by week 16."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were randomly assigned to receive monthly 6 or 12 mg/kg NPC-21, or placebo, in a 4:1:4 ratio."
      },
      "Blinding": {
        "score": 3,
        "evidence": "This was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Eighty-seven KT recipients were randomized; 38, 11, and 38 received 6 mg/kg of NPC-21, 12 mg/kg of NPC-21, or placebo, respectively."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "CMV infections occurred in 29 of 38 (76.3%), 9 of 11 (81.8%), and 26 of 38 (68.4%) patients in the 6 mg/kg NPC-21, 12 mg/kg NPC-21, and placebo groups, respectively."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The absolute difference (95% confidence interval) was −9.1 (−23.9 to 2.8)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were observed after NPC-21 administration."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}